

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AOYAGI ET AL.

Examiner:

D. WORTMAN

RECEIVED

Filed:

09/509,449

Group Art Unit:

1648

.!!!L 1 9 2001

Due Date:

MARCH 28, 2000 JULY 12, 2001

Docket:

594.352USWO

TECH CENTER 1600/2900

Title:

METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, D.C. 20231, on July

Box Sequence Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

☐ Transmittal Sheet in duplicate containing Certificate of Mailing

Computer readable form of Sequence Listing. Applicants state that the paper copy form of the Sequence Listing section of the present application, and the computer readable form submitted herewith, are the same.

Other: Response to Notice to Comply and Certificate Regarding Sequence Listing and copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Peposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C. P.O. Box 2903, Minneapolis, MN 55402-0903 612.332.5300

PATENT TRADEMARK OFFICE

Name: Douglas P. Mueller

Reg. No.: 30,300 DMueller:PSTkaw





TECH CENTER 1600/2900

and & al PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

AOYAGI ET AL.

Examiner:

D. WORTMAN

Serial No.:

09/509,449

Group Art Unit:

1648

Filed:

MARCH 28, 2000

Docket No.:

594.352USWO

Title:

METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on July 2, 2001.

By:\_\_\_ Name:

RESPONSE TO NOTICE TO COMPLY AND CERTIFICATE REGARDING SEQUENCE LISTING

Box Sequence Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This paper is being filed in response to the Examiner's communication mailed June 12, 2001. In response to the Notice to Comply and in accordance with the requirements of 37 C.F.R. § 1.821 - § 1.825, Applicants enclose herewith a substitute computer readable form of the Sequence Listing. Please insert the substitute paper copy into the file. Applicants state that the substitute paper copy of the Sequence Listing of the present application and the computer readable form submitted herewith are the same. Applicants hereby state that the substitute computer readable form and the paper copy of the Sequence Listing enclosed do not include new matter. The examiner is invited to contact Applicants' representative if there are any questions or concerns regarding the substitute sequence listing.

Pursuant to the Exampler's request, also enclosed is a copy of the Notice to Comply with the sequence listing rules.

Respectfully submitted,

MERCHANT & GOULD P.C.

P.O. Box 2903 Minneapolis, Minnesota 55402-0903 (612) 332-5300

Date: Jun 13 2001

Douglas P. Mueller Reg. No. 30,300

DPM:PSTkaw

plicati n No.: 1. NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

7. Other:

## Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE